Thursday, GSK plc (LSE/NYSE:GSK) announced headline results of a phase 2 trial for its mRNA seasonal influenza vaccine program.
The trial studied a range of mRNA formulations in older and younger adults to evaluate vaccine candidates that could improve immune responses against influenza A and B strains, compared to the current standard of care.
The data demonstrated positive immune responses against influenza A and B strains compared to the current standard of care, meeting all predefined success criteria in the tested age groups of older ...
